Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Adding a chatbot to specialist care helped young people make sense of cancer risk (opens in a new tab)

news-medical.net · 2026-10-12

Short answerEvidenceSource

Short answer

Mostly supported

Mostly supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 6 supported
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly supported

Every claim we could check holds up. Six of eight claims match the study. This overall rating is based only on the claims we could check. Two claims the study doesn't address.

  • 6 supported
  • 2 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

8 claims in this story

Showing all 8 claimsChoose a verdict to focus the list.

Claim 1 of 8Not coveredLifetime cancer risk results did not differ significantly between groups, and screening knowledge improvement was not significant in the main analysis.View evidenceHide evidence

Why this verdict

The profile supports the screening-knowledge portion: improvement favored the intervention but was not statistically significant in the abstract-level results. However, although lifetime cancer risk knowledge is mentioned as part of the objective/contribution, the supplied abstract-depth profile does not provide a lifetime-risk result or significance test. Therefore the full combined claim cannot be verified at this depth.

1

Study evidence

The chatbot plus clinic visit resulted in greater improvement in accurate knowledge of cancer risk by age 30 years compared with clinic visit alone.OR 3.50 (95% CI, 1.45–9.19); P = .005

“This randomized clinical trial was conducted at the Dana-Farber Cancer Institute, Emory University/Children's Healthcare of Atlanta, University of Chicago, and University of Utah Huntsman Cancer Institute”
2

Study evidence

Knowledge of recommended screening showed an estimated improvement in the chatbot intervention group compared with control, but the difference was not statistically significant.OR, 2.17; 95% CI, 0.85-5.59; P = .11

“The secondary outcomes were knowledge of recommended screening and level of psychological distress.”
Claim 2 of 8Not coveredThe article says enrollment fell short of the original 300-person target, the sample was predominantly White and drawn from specialist centers, and the reported results do not show whether knowledge gains persisted or led to better screening adherence or health outcomes.View evidenceHide evidence

As stated106 AYAs enrolled; original target 300

Why this verdict

The abstract-level profile supports some elements, including 106 randomized participants and recruitment from four academic cancer centers, and it includes generalizability limitations to represented clinical settings. But it does not verify the original 300-person target, the proportion of approached eligible AYAs who enrolled, the sample being predominantly White, or whether knowledge gains persisted or translated into screening adherence or health outcomes. Those details may require full-text evidence.

1

Study evidence

The chatbot plus clinic visit resulted in greater improvement in accurate knowledge of cancer risk by age 30 years compared with clinic visit alone.OR 3.50 (95% CI, 1.45–9.19); P = .005

“This randomized clinical trial was conducted at the Dana-Farber Cancer Institute, Emory University/Children's Healthcare of Atlanta, University of Chicago, and University of Utah Huntsman Cancer Institute”
2

Study evidence

Knowledge of recommended screening showed an estimated improvement in the chatbot intervention group compared with control, but the difference was not statistically significant.OR, 2.17; 95% CI, 0.85-5.59; P = .11

“The secondary outcomes were knowledge of recommended screening and level of psychological distress.”
Claim 3 of 8SupportedResearchers tested whether a chatbot-based intervention could strengthen the information young people with hereditary cancer syndromes receive in specialist care.View evidenceHide evidence

Why this verdict

The abstract-level profile states that the trial evaluated whether adding a tailored electronic chatbot-based cancer risk communication tool to a cancer predisposition clinic visit improved adolescents’ and young adults’ cancer risk knowledge compared with clinic visit alone. The story’s hedged framing that researchers tested whether the chatbot could strengthen specialist-care information is consistent with that objective.

1

Study evidence

The chatbot plus clinic visit resulted in greater improvement in accurate knowledge of cancer risk by age 30 years compared with clinic visit alone.OR 3.50 (95% CI, 1.45–9.19); P = .005

“This randomized clinical trial was conducted at the Dana-Farber Cancer Institute, Emory University/Children's Healthcare of Atlanta, University of Chicago, and University of Utah Huntsman Cancer Institute”
Claim 4 of 8SupportedIn a recent study published in JAMA Network Open, researchers assessed how a chatbot-based intervention affected cancer risk understanding among adolescents and young adults with hereditary cancer predisposition.View evidenceHide evidence

Why this verdict

The paper profile describes a randomized clinical trial assessing a chatbot-based cancer risk communication tool in adolescents and young adults with hereditary cancer predisposition syndromes, with cancer risk knowledge as the primary outcome. The journal attribution is not independently evaluated here, but the scientific claim matches the supplied profile.

1

Study evidence

The chatbot plus clinic visit resulted in greater improvement in accurate knowledge of cancer risk by age 30 years compared with clinic visit alone.OR 3.50 (95% CI, 1.45–9.19); P = .005

“This randomized clinical trial was conducted at the Dana-Farber Cancer Institute, Emory University/Children's Healthcare of Atlanta, University of Chicago, and University of Utah Huntsman Cancer Institute”
Claim 5 of 8SupportedIn a randomized trial at four US academic centers, participants received either a cancer predisposition clinic visit plus AYA-RISE or a clinic visit alone.View evidenceHide evidence

As statedrandomized trial at four US academic centers

Why this verdict

The profile states that this was a multicenter randomized clinical trial at four US centers comparing cancer predisposition clinic visit alone versus clinic visit plus AYA-RISE/chatbot. This supports the story’s description of the design, setting, and arms.

1

Study evidence

The chatbot plus clinic visit resulted in greater improvement in accurate knowledge of cancer risk by age 30 years compared with clinic visit alone.OR 3.50 (95% CI, 1.45–9.19); P = .005

“This randomized clinical trial was conducted at the Dana-Farber Cancer Institute, Emory University/Children's Healthcare of Atlanta, University of Chicago, and University of Utah Huntsman Cancer Institute”
Claim 6 of 8SupportedKnowledge of cancer risk before age 30 was the primary outcome, with screening knowledge and psychological distress as secondary outcomes.View evidenceHide evidence

Why this verdict

The profile identifies knowledge of cancer risk by age 30 years as the primary outcome and knowledge of recommended screening plus psychological distress as secondary outcomes. The claim is aligned with the abstract-level evidence.

1

Study evidence

The chatbot plus clinic visit resulted in greater improvement in accurate knowledge of cancer risk by age 30 years compared with clinic visit alone.OR 3.50 (95% CI, 1.45–9.19); P = .005

“This randomized clinical trial was conducted at the Dana-Farber Cancer Institute, Emory University/Children's Healthcare of Atlanta, University of Chicago, and University of Utah Huntsman Cancer Institute”
2

Study evidence

Knowledge of recommended screening showed an estimated improvement in the chatbot intervention group compared with control, but the difference was not statistically significant.OR, 2.17; 95% CI, 0.85-5.59; P = .11

“The secondary outcomes were knowledge of recommended screening and level of psychological distress.”
Claim 7 of 8SupportedAt follow-up, accurate knowledge of cancer risk before age 30 improved more in the intervention group than in controls, rising from 52% to 78% versus 38% to 37%.View evidenceHide evidence

As stated52% to 78% versus 38% to 37%

Why this verdict

The profile reports baseline accurate knowledge of cancer risk by age 30 of 52% in the intervention group and 38% in controls, with post-visit values of 78% and 37%, respectively, and a statistically significant intervention effect (OR 3.50; 95% CI, 1.45–9.19; P = .005). The story’s causal framing is acceptable because this was a randomized trial.

1

Study evidence

The chatbot plus clinic visit resulted in greater improvement in accurate knowledge of cancer risk by age 30 years compared with clinic visit alone.OR 3.50 (95% CI, 1.45–9.19); P = .005

“This randomized clinical trial was conducted at the Dana-Farber Cancer Institute, Emory University/Children's Healthcare of Atlanta, University of Chicago, and University of Utah Huntsman Cancer Institute”
Claim 8 of 8SupportedThe intervention did not increase psychological distress, but it also did not show an additional well-being benefit.View evidenceHide evidence

Why this verdict

The profile reports that psychological distress reductions favored the intervention but were not statistically significant (β = -0.50; 95% CI, -1.09 to 0.08; P = .09), and the discussion notes improvement in risk knowledge without increasing distress. The story’s wording that there was no increase in distress and no clear added well-being benefit is consistent with the non-significant distress finding.

1

Study evidence

The chatbot plus clinic visit resulted in greater improvement in accurate knowledge of cancer risk by age 30 years compared with clinic visit alone.OR 3.50 (95% CI, 1.45–9.19); P = .005

“This randomized clinical trial was conducted at the Dana-Farber Cancer Institute, Emory University/Children's Healthcare of Atlanta, University of Chicago, and University of Utah Huntsman Cancer Institute”
2

Study evidence

Knowledge of recommended screening showed an estimated improvement in the chatbot intervention group compared with control, but the difference was not statistically significant.OR, 2.17; 95% CI, 0.85-5.59; P = .11

“The secondary outcomes were knowledge of recommended screening and level of psychological distress.”
Then look for missing context

Context layer

What the story carried across

Nothing material from the study was dropped.

8 things the story did carry across
  • The paper’s central design was a multicenter parallel-group randomized clinical trial comparing clinic visit alone with clinic visit plus a tailored chatbot-based AYA-RISE cancer risk communication intervention.
  • The study population was adolescents and young adults aged 12–24 years with hereditary cancer predisposition syndromes.
  • The primary endpoint was accurate knowledge of cancer risk by age 30 years, assessed by baseline and follow-up surveys.
  • The primary result was a statistically significant greater improvement in accurate knowledge of cancer risk by age 30 in the chatbot group versus control.
  • Secondary outcomes included knowledge of recommended screening and psychological distress, and both favored the intervention numerically but did not reach statistical significance.
  • The abstract-level profile indicates lifetime cancer risk knowledge was part of the risk-knowledge objective, but the supplied profile does not provide an abstract-level lifetime-risk result.
  • The trial randomized 106 participants, with 54 in the intervention arm and 52 in the control arm.
  • A material limitation in the supplied profile is that secondary-outcome analyses were not primary endpoints and may have been underpowered, with confidence intervals including the null.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoEvaluate whether adding a tailored electronic chatbot-based cancer risk communication tool to a cancer predisposition clinic visit improves adolescents’ and young adults’ (ages 12-24) knowledge of cancer risk (by age 30 years and lifetime) compared with clinic visit alone.Multicenter parallel-group randomized clinical trial (clinic visit alone vs clinic visit + tailored chatbot)Expand

In plain English

Multicenter randomized clinical trial (parallel-group) comparing a tailored chatbot-based cancer risk communication tool plus a cancer predisposition clinic visit versus the clinic visit alone in adolescents and young adults (ages 12–24) with hereditary cancer predisposition syndromes. Primary outcome was knowledge of cancer risk (by age 30 years); secondary outcomes were knowledge of recommended screening and psychological distress. In 106 randomized participants (54 intervention, 52 control) the chatbot arm showed greater improvement in accurate knowledge of cancer risk by age 30 years (OR 3.50, 95% CI 1.45–9.19, P = .005). Improvements in screening knowledge and reductions in distress favored the intervention but did not reach statistical significance.

Key findings

  • The chatbot plus clinic visit resulted in greater improvement in accurate knowledge of cancer risk by age 30 years compared with clinic visit alone.OR 3.50 (95% CI, 1.45–9.19); P = .005
  • Knowledge of recommended screening improved in the intervention group compared with control, but the difference did not reach statistical significance.OR 2.17 (95% CI, 0.85–5.59); P = .11
“This randomized clinical trial was conducted at the Dana-Farber Cancer Institute, Emory University/Children's Healthcare of Atlanta, University of Chicago, and University of Utah Huntsman Cancer Institute”
2human in vivoAssess secondary effects of the chatbot intervention on (a) knowledge of recommended screening and (b) psychological distress after the clinic visit.Secondary outcomes within randomized clinical trialExpand

In plain English

Secondary-outcome analyses from the randomized clinical trial compared the chatbot-plus-clinic visit versus clinic visit alone on (a) knowledge of recommended screening and (b) psychological distress (distress thermometer), using the same baseline and post–clinic-visit follow-up surveys. Reported effects favored the intervention for both outcomes but did not reach statistical significance.

Key findings

  • Knowledge of recommended screening showed an estimated improvement in the chatbot intervention group compared with control, but the difference was not statistically significant.OR, 2.17; 95% CI, 0.85-5.59; P = .11
  • Psychological distress (distress thermometer) was lower in the intervention group by an estimated 0.50 points, but this reduction did not reach statistical significance.β = -0.50; 95% CI, -1.09 to 0.08; P = .09
“The secondary outcomes were knowledge of recommended screening and level of psychological distress.”
What this piece can’t prove
  • Analyses are secondary-outcome assessments within the same RCT; not powered as primary endpoints may be.
  • Reported effect estimates did not reach statistical significance and confidence intervals include the null.
  • Generalizability limited to English-speaking AYAs aged 12–24 years with one of nine specified hereditary cancer predisposition syndromes and to the clinical settings represented.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

And 9 more candidates considered.